

US009486583B2

# (12) United States Patent

### Lannan et al.

### (54) PREFILLED SYRINGE WITH BREAKAWAY FORCE FEATURE

- (71) Applicant: ANTARES PHARMA, INC., Ewing, NJ (US)
- (72) Inventors: James W. Lannan, Brooklyn Center, MN (US); Julius C. Sund, Plymouth, MN (US)
- (73) Assignee: Antares Pharma, Inc., Ewing, NJ (US)
- (\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 136 days.
- (21) Appl. No.: 13/785,582
- (22) Filed: Mar. 5, 2013

### (65) **Prior Publication Data**

US 2013/0237921 A1 Sep. 12, 2013

### **Related U.S. Application Data**

- (60) Provisional application No. 61/607,339, filed on Mar. 6, 2012.
- (51) Int. Cl. *A61M 5/20* (2006.01)
- (52) U.S. Cl. CPC .... *A61M 5/2033* (2013.01); *A61M 2005/2073* (2013.01)

# (10) Patent No.: US 9,486,583 B2

### (45) **Date of Patent:** Nov. 8, 2016

#### (56) **References Cited**

### U.S. PATENT DOCUMENTS

3,688,765 A	9/1972	Gasaway
3,712,301 A	1/1973	Sarnoff
3,797,489 A	3/1974	Sarnoff
3,882,863 A	5/1975	Sarnoff et al.
4,484,910 A	11/1984	Sarnoff et al.
4,558,690 A	12/1985	Joyce

(Continued)

### FOREIGN PATENT DOCUMENTS

AR	00081651	10/2012
AR	082053	11/2012
	(6	

(Continued)

### OTHER PUBLICATIONS

International Search Report for International Patent Application No. PCT/US2013/029085, dated May 13, 2013, 2 pages. (Continued)

Communi


Primary Examiner — Nathan R Price


Assistant Examiner — Weng Lee (74) Attorney, Agent, or Firm — Morgan Lewis & Bockius LLP

### (57) **ABSTRACT**

A jet injector that includes a prefilled syringe. The syringe includes a fluid chamber that contains a medicament. The syringe also has an injection-assisting needle, and a plunger is movable within the fluid chamber. A housing is configured for allowing insertion of the needle to a penetration depth. The housing includes a retractable guard and an interference component, e.g., a lock ring, adjacent to the retractable guard that interferes with the movement of the retractable guard. An energy source is configured for biasing the plunger to produce an injecting pressure to jet inject the medicament from the fluid chamber through the needle to an injection site.

### 22 Claims, 11 Drawing Sheets





#### (56) **References** Cited

# U.S. PATENT DOCUMENTS

0.0		
4,624,660 A	11/1986	Mijers et al.
4,661,098 A	4/1987	Bekkering et al.
4,664,653 A	5/1987	Sagstetter et al.
4,678,461 A	7/1987	Mesa
4,820,286 A	4/1989	van der Wal
4,822,340 A	4/1989	Kamstra
4,986,816 A	1/1991 8/1991	Steiner et al. Bechtold et al.
5,042,977 A 5.078,680 A	1/1991	Sarnoff
5,078,680 A 5,085,641 A	2/1992	Sarnoff et al.
5,085,642 A	2/1992	Sarnoff et al.
5,092,842 A	3/1992	Bechtold et al.
5,102,393 A	4/1992	Sarnoff et al.
5,114,406 A	5/1992	Gabriel et al.
5,163,907 A	11/1992	Szuszkiewicz
5,176,643 A	1/1993	Kramer et al.
5,180,370 A	1/1993	Gillespie
5,195,983 A	3/1993	Boese
5,271,744 A 5,279,543 A	12/1993 1/1994	Kramer et al. Glikfeld et al.
5,300,030 A	4/1994	Crossman et al.
5,342,308 A	8/1994	Boschetti
5,354,286 A	10/1994	Mesa et al.
5,358,489 A	10/1994	Wyrick
5,391,151 A	2/1995	Wilmot
5,425,715 A	6/1995	Dalling et al.
5,478,316 A	12/1995	Bitdinger et al.
5,514,097 A	5/1996	Knauer
5,540,664 A	7/1996	Wyrick
5,567,160 A 5,569,192 A	10/1996 10/1996	Massino van der Wal
5,569,192 A 5,593,388 A	1/1997	Phillips
5,599,302 A	2/1997	Lilley et al.
5,658,259 A	8/1997	Pearson et al.
5,665,071 A	9/1997	Wyrick
5,695,472 A	12/1997	Wyrick
5,820,602 A	10/1998	Kovelman et al.
5,836,911 A	11/1998	Marzynski et al
5,843,036 A	12/1998	Olive et al.
5,851,197 A 5.891.085 A	12/1998	Marano et al.
5,891,085 A 5,891,086 A	4/1999 4/1999	Lilley et al. Weston
5,919,159 A	7/1999	Lilley et al.
5,935,949 A	8/1999	White
6,045,534 A	4/2000	Jacobson et al.
6,077,247 A	6/2000	Marshall et al.
6,090,070 A	7/2000	Hager et al.
6,099,504 A	8/2000	Gross et al.
6,102,896 A	8/2000	Roser
6,203,529 B1 6,210,369 B1	3/2001 4/2001	Gabriel et al. Wilmot et al.
6,210,369 B1 6,221,046 B1	4/2001	Burroughs et al.
6,241,709 B1	6/2001	Bechtold et al.
6,245,347 B1	6/2001	Zhang et al.
6,270,479 B1	8/2001	Bergens et al.
6,371,939 B2	4/2002	Bergens et al.
6,391,003 B1	5/2002	Lesch, Jr.
6,428,528 B2	8/2002	Sadowski et al.
6,517,517 B1	2/2003	Farrugia et al.
6,530,904 B1	3/2003 4/2003	Edwards et al.
6,544,234 B1 6,565,553 B2	5/2003	Gabriel Sadowski et al.
6,569,123 B2	5/2003	Alchas et al.
6,569,143 B2	5/2003	Alchas et al.
6,607,508 B2	8/2003	Knauer
6,641,561 B1	11/2003	Hill et al.
6,656,150 B2	12/2003	Hill et al.
6,673,035 B1	1/2004	Rice et al.
6,682,504 B2	1/2004	Nelson et al.
6,746,429 B2	6/2004	Sadowski et al.
6,767,336 B1	7/2004	Kaplan Grees et el
6,830,560 B1	12/2004	Gross et al. Marshall et al.
6,932,793 B1 6,932,794 B2	8/2005 8/2005	Giambattista et al.
6,969,370 B2	11/2005	Langley et al.
5,565,570 BZ	11/2003	Langrey et al.

6,969,372 B1	11/2005	Halseth
6,979,316 B1	12/2005	Rubin et al.
6,986,758 B2	1/2006	Schiffmann
6,997,901 B2	2/2006	Popovsky
7,066,907 B2	6/2006	Crossman et al.
7,118,553 B2	10/2006	Scherer
	1/2007	Bendek et al.
/ /		
7,195,616 B2	3/2007	Diller et al.
7,218,962 B2	5/2007	Freyman
7,247,149 B2	7/2007	Beyerlein
7,291,132 B2	11/2007	DeRuntz et al.
7,292,885 B2	11/2007	Scott et al.
7,297,136 B2	11/2007	Wyrick
7,341,575 B2	3/2008	Rice et al.
7,361,160 B2	4/2008	Hommann et al.
7,390,314 B2	6/2008	Stutz, Jr. et al.
7,390,319 B2	6/2008	Friedman
	8/2008	Gurtner
/ /		
7,416,540 B2	8/2008	Edwards et al.
7,449,012 B2	11/2008	Young et al.
7,488,308 B2	2/2009	Lesch, Jr.
7,488,313 B2	2/2009	Segal et al.
7,488,314 B2	2/2009	Segal et al.
7,517,342 B2	4/2009	Scott et al.
7,519,418 B2	4/2009	Scott et al.
7,544,188 B2	6/2009	Edwards et al.
7,547,293 B2	6/2009	Williamson et al.
7,569,035 B1	8/2009	Wilmot et al.
7,611,491 B2	11/2009	Pickhard
7,621,887 B2	11/2009	Griffiths et al.
7,621,891 B2	11/2009	Wyrick
7,635,348 B2	12/2009	Raven et al.
7,637,891 B2	12/2009	Wall
7,648,482 B2	1/2010	Edwards et al.
7,648,483 B2	1/2010	Edwards et al.
7,654,983 B2	2/2010	De La Sema et al.
7,658,724 B2	2/2010	Rubin et al.
7,670,314 B2	3/2010	Wall et al.
7,704,237 B2	4/2010	Fisher et al.
7,717,877 B2	5/2010	Lavi et al.
7,722,595 B2	5/2010	Pettis et al.
7,731,686 B2	6/2010	Edwards et al.
7,731,690 B2	6/2010	Edwards et al.
7,736,333 B2	6/2010	Gillespie, III
7,744,582 B2	6/2010	Sadowski et al.
7,749,194 B2	7/2010	Edwards et al.
7,749,195 B2	7/2010	Hommann
7,762,996 B2	7/2010	Palasis
7,776,015 B2	8/2010	Sadowski et al.
7,794,432 B2	9/2010	Young et al.
7,811,254 B2	10/2010	Wilmot et al.
7,862,543 B2	1/2011	Potter et al.
7,896,841 B2	3/2011	Wall et al.
7,901,377 B1	3/2011	
		Harrison et al.
	3/2011	Wyrick
7,905,866 B2	3/2011	Haider et al.
7,918,823 B2	4/2011	Edwards et al.
7,927,303 B2	4/2011	Wyrick
7,931,618 B2	4/2011	Wyrick
7,947,017 B2	5/2011	Edwards et al.
RE42,463 E	6/2011	Landau
7,955,304 B2	6/2011	Guillermo
7,967,772 B2	6/2011	McKenzie et al.
7,988,675 B2	8/2011	Gillespie, III et al.
8,016,774 B2	9/2011	Freeman et al.
8,016,788 B2	9/2011	Edwards et al.
8,021,335 B2	9/2011	
	11/2011	Lesch, Jr. Mesa et al
8,048,035 B2	1177011	Mesa et al.
8,048,037 B2		Kahlbronnan at -1
	11/2011	Kohlbrenner et al.
8,057,427 B2	11/2011 11/2011	Griffiths et al.
8,066,659 B2	11/2011 11/2011 11/2011	
8,066,659 B2 8,083,711 B2	11/2011 11/2011	Griffiths et al.
8,066,659 B2 8,083,711 B2	11/2011 11/2011 11/2011	Griffiths et al. Joshi et al.
8,066,659 B2 8,083,711 B2 8,100,865 B2	11/2011 11/2011 11/2011 12/2011 1/2012	Griffiths et al. Joshi et al. Enggaard Spofforth
8,066,659 B2 8,083,711 B2 8,100,865 B2 8,105,272 B2	11/2011 11/2011 11/2011 12/2011 1/2012 1/2012	Griffiths et al. Joshi et al. Enggaard Spofforth Williamson et al.
8,066,659 B2 8,083,711 B2 8,100,865 B2 8,105,272 B2 8,105,281 B2	11/2011 11/2011 11/2011 12/2011 1/2012 1/2012 1/2012	Griffiths et al. Joshi et al. Enggaard Spofforth Williamson et al. Edwards et al.
8,066,659 B2 8,083,711 B2 8,100,865 B2 8,105,272 B2 8,105,281 B2 8,110,209 B2	11/2011 11/2011 12/2011 1/2012 1/2012 1/2012 2/2012	Griffiths et al. Joshi et al. Enggaard Spofforth Williamson et al. Edwards et al. Prestrelski et al.
8,066,659 B2 8,083,711 B2 8,100,865 B2 8,105,272 B2 8,105,281 B2 8,110,209 B2 8,123,719 B2	11/2011 11/2011 11/2011 1/2012 1/2012 1/2012 2/2012 2/2012	Griffiths et al. Joshi et al. Enggaard Spofforth Williamson et al. Edwards et al. Prestrelski et al. Edwards et al.
8,066,659 B2 8,083,711 B2 8,100,865 B2 8,105,272 B2 8,105,281 B2 8,110,209 B2 8,123,719 B2 8,123,724 B2	11/2011 11/2011 11/2011 12/2011 1/2012 1/2012 2/2012 2/2012 2/2012	Griffiths et al. Joshi et al. Enggaard Spofforth Williamson et al. Edwards et al. Prestrelski et al. Edwards et al. Gillespie, III
8,066,659 B2 8,083,711 B2 8,100,865 B2 8,105,272 B2 8,105,281 B2 8,110,209 B2 8,123,719 B2	11/2011 11/2011 11/2011 1/2012 1/2012 1/2012 2/2012 2/2012	Griffiths et al. Joshi et al. Enggaard Spofforth Williamson et al. Edwards et al. Prestrelski et al. Edwards et al.

#### (56) **References** Cited

# U.S. PATENT DOCUMENTS

L	J.S.	PATENT	DOCUMENTS
8,162,886 H	B2	4/2012	Sadowski et al.
	B2	5/2012	Matusch
	B2	5/2012	Klein
8,177,758 H	B2	5/2012	Brooks, Jr. et al.
- , ,	B2	5/2012	Wyrick Taabirran at al
, ,	B2 B2	7/2012 7/2012	Tschirren et al. Burroughs et al.
/ /	B2	7/2012	Geertsen
	B2	7/2012	Boyd et al.
8,233,135 H	B2	7/2012	Jansen et al.
	B2	8/2012	Wikner
	B2	8/2012	Schrul et al.
· · ·	B2 B2	8/2012 9/2012	Kramer et al. Thogersen et al.
	B2	9/2012	Plumptre
	B2	9/2012	Moller
· · ·	B2	9/2012	Harms et al.
· · · ·	B2	9/2012	Bausch et al.
· · ·	B2 B2	9/2012 10/2012	Adachi et al. Farieta et al.
	B2	10/2012	Kronestedt
	B2	10/2012	Kirchhofer
	B2	10/2012	Hirschel et al.
	B2	10/2012	Moller
· · ·	B2	10/2012	Terada
RE43,834 H	E B2	11/2012 11/2012	Steenfeldt-Jensen et al.
	Б2 В2	11/2012	Zamperla et al. Laiosa
- , ,	B2	11/2012	Edwards et al.
8,317,757 H	B2	11/2012	Plumptre
8,323,237 H	B2	12/2012	Radmer et al.
, ,	B2	12/2012	Moller
- , , = =	B2 B2	12/2012 1/2013	Edginton et al. Moser
	B2	1/2013	Marshall et al.
	B2	1/2013	Radmer et al.
, ,	B2	1/2013	Moller et al.
	B2	1/2013	Moller et al.
· · ·	B2 B2	1/2013 1/2013	Grunhut et al. Moller et al.
	B2 B2	2/2013	Raab
, ,	B2	2/2013	Elmen et al.
	B2	2/2013	Wieselblad
	B2	2/2013	Cox et al.
· · ·	B2	3/2013	Eich et al. Hommann et al.
	B2 B2	4/2013 5/2013	Abry et al.
	B2	10/2013	Lesch
	B2	8/2014	Sund et al.
	A1	11/2001	Weston
	A1	11/2002	Polzin
	A1 A1	2/2003 9/2003	Pass et al. Farrugia et al.
	A1	2/2003	Letzing
	<b>A</b> 1	7/2004	Hunter et al.
	<b>A</b> 1	11/2004	Sadowski et al.
	41	12/2004	Scott et al.
	A1 A1	2/2005 5/2005	Lavi et al.
	A1	7/2005	Brunnberg Judson et al.
	AI	9/2005	Ishikawa et al.
2005/0215955 A	41	9/2005	Slawson
	<b>A</b> 1	10/2005	Scott et al.
	A1	11/2005	Pettis et al.
	A1 A1	12/2005 5/2006	Asch Pass et al.
	A1	6/2006	Wyrick
	A1	10/2006	Scherer
2006/0258988 A	<b>A</b> 1	11/2006	Keitel et al.
	A1	11/2006	Weber
	A1	1/2007	Wyrick
	A1	2/2007	Joshi et al. Hommann
	A1 A1	2/2007 5/2007	Hommann Bozeman et al.
	41	5/2007	Griffiths et al.
1	••	2,2007	

2007/0129687 A1	6/2007	Marshall et al.
2007/0185432 A1	8/2007	Etheredge et al.
2007/0191784 A1	8/2007	Jacobs et al.
2007/0219498 A1	9/2007	Malone et al.
2008/0059133 A1	3/2008	Edwards et al.
2008/0154199 A1	6/2008	Wyrick
2008/0262427 A1	10/2008	Hommann
2008/0262436 A1	10/2008	Olson
2008/0262445 A1	10/2008	Hsu et al.
2009/0124981 A1	5/2009	Evans
2009/0124997 A1	5/2009	Pettis et al.
2009/0204062 A1	8/2009	Muto et al.
2009/0254035 A1	10/2009	Kohlbrenner et al.
2009/0299278 A1	12/2009	Lesch, Jr. et al.
2009/0304812 A1	12/2009	Stainforth et al.
2009/0318361 A1	12/2009	Noera et al.
2010/0036318 A1	2/2010	Raday et al.
2010/0049125 A1	2/2010	James et al.
2010/0069845 A1	3/2010	Marshall et al.
2010/0076378 A1	3/2010	Runfola
2010/0076400 A1	3/2010	Wall
2010/0087847 A1	4/2010	Hong
2010/0094214 A1	4/2010	Abry et al.
2010/0094214 A1 2010/0094324 A1	4/2010	
		Huang et al.
2010/0100039 A1	4/2010	Wyrick
2010/0152699 A1	6/2010	Ferrari et al.
2010/0152702 A1	6/2010	Vigil et al.
2010/0160894 A1	6/2010	Julian et al.
2010/0168677 A1	7/2010	Gabriel et al.
2010/0174268 A1	7/2010	Wilmot et al.
2010/0204678 A1	8/2010	Imran
2010/0217105 A1	8/2010	Yodfat et al.
2010/0228193 A1	9/2010	Wyrick
2010/0249746 A1	9/2010	Klein
2010/0256570 A1	10/2010	Maritan
2010/0258631 A1	10/2010	Rueblinger et al.
2010/0262082 A1	10/2010	Brooks et al.
2010/0274198 A1	10/2010	Bechtold
2010/0274273 A1	10/2010	Schraga et al.
2010/0288593 A1	11/2010	Chiesa et al.
2010/0292643 A1	11/2010	Wilmot et al.
2010/0298780 A1	11/2010	Laiosa
2010/0312196 A1	12/2010	Hirschel et al.
2010/0318035 A1	12/2010	Edwards et al.
2010/0318037 A1	12/2010	Young et al.
2010/0324480 A1	12/2010	Chun
2011/0021989 A1	1/2011	Janek et al.
	3/2011	
		Shang et al.
2011/0077599 A1	3/2011	Wozencroft
2011/0087192 A1	4/2011	Uhland et al.
2011/0098655 A1	4/2011	Jennings et al.
2011/0125076 A1	5/2011	Kraft et al.
2011/0125100 A1	5/2011	Schwirtz et al.
2011/0137246 A1	6/2011	
2011/0144594 A1*	6/2011	Sund et al 604/228
2011/0190725 A1	8/2011	Pettis et al.
2011/0196300 A1	8/2011	Edwards et al.
2011/0196311 A1	8/2011	Bicknell et al.
2011/0224620 A1	9/2011	Johansen et al.
2011/0238003 A1	9/2011	Bruno-Raimondi et al.
2011/0269750 A1	11/2011	Kley et al.
2011/0319864 A1	12/2011	Beller et al.
2012/0004608 A1*	1/2012	Lesch, Jr 604/135
2012/0016296 A1	1/2012	Charles
2012/0046609 A1	2/2012	Mesa et al.
2012/0053563 A1	3/2012	Du
2012/0059319 A1	3/2012	Segal
2012/0071829 A1	3/2012	Edwards et al.
2012/0095443 A1	4/2012	Ferrari et al.
2012/0101475 A1	4/2012	Wilmot et al.
2012/01014/5 A1 2012/0116318 A1	5/2012	Edwards et al.
2012/0123350 A1	5/2012	Giambattista et al.
2012/0123385 A1	5/2012	Edwards et al.
2012/0130318 A1	5/2012	Young
2012/0130342 A1	5/2012	Cleathero
2012/0136303 A1	5/2012	Cleathero
	5/2012	Cicalicio
2012/0136318 A1	5/2012	Lanin et al.
2012/0136318 A1 2012/0143144 A1		
	5/2012	Lanin et al.

# (56) **References Cited**

### U.S. PATENT DOCUMENTS

2012/0157965 A1		
	6/2012	Wotton et al.
2012/0172809 A1	7/2012	Plumptre
2012/0172811 A1	7/2012	Enggaard et al.
	7/2012	
2012/0172812 A1		Plumptre et al.
2012/0172813 A1	7/2012	Plumptre et al.
2012/0172814 A1	7/2012	Plumptre et al.
2012/0172815 A1	7/2012	Holmqvist
2012/0172816 A1	7/2012	Boyd et al.
2012/0172818 A1	7/2012	Harms et al.
2012/0179100 A1	7/2012	Sadowski et al.
2012/0179137 A1	7/2012	Bartlett et al.
2012/0184900 A1	7/2012	Marshall et al.
2012/0184917 A1	7/2012	Bom et al.
2012/0184918 A1	7/2012	Bostrom
2012/0186075 A1	7/2012	Edginton
2012/0191048 A1	7/2012	Eaton
2012/0191049 A1	7/2012	Harms et al.
2012/0197209 A1	8/2012	Bicknell et al.
2012/0197213 A1	8/2012	Kohlbrenner et al.
2012/0203184 A1	8/2012	Selz et al.
2012/0203185 A1	8/2012	Kristensen et al.
2012/0203186 A1	8/2012	Vogt et al.
2012/0209192 A1	8/2012	Alexandersson
2012/0209200 A1	8/2012	Jones et al.
2012/0209210 A1	8/2012	Plumptre et al.
2012/0209211 A1	8/2012	Plumptre et al.
2012/0209212 A1	8/2012	Plumptre et al.
2012/0215162 A1	8/2012	Nielsen et al.
2012/0215176 A1	8/2012	Veasey et al.
2012/0220929 A1	8/2012	Nagel et al.
2012/0220941 A1	8/2012	Jones
2012/0220953 A1	8/2012	Holmqvist
2012/0220954 A1	8/2012	Cowe
2012/0226226 A1	9/2012	Edwards et al.
2012/0230620 A1	9/2012	Holdgate et al.
2012/0232517 A1	9/2012	Saiki
2012/0245516 A1	9/2012	Tschirren et al.
2012/0245532 A1	9/2012	Frantz et al.
2012/0253274 A1	10/2012	Karlsson et al.
	10/2012	Giambattista et al.
2012/0253288 A1	10/2012	Dasbach et al.
2012/0253289 A1	10/2012	Cleathero
2012/0253290 A1	10/2012	Geertsen
2012/0253314 A1	10/2012	Harish et al.
2012/0259285 A1	10/2012	Schabbach et al.
	10/2012	Jugl et al.
2012/0265153 A1		
2012/0267761 A1	10/2012	Kim et al.
2012/0267761 A1 2012/0271233 A1	10/2012 10/2012	Kim et al. Bruggemann et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1	10/2012 10/2012 10/2012	Kim et al. Bruggemann et al. Plumptre et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/0277724 A1	10/2012 10/2012 10/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/0277724 A1 2012/0283645 A1	10/2012 10/2012 10/2012 11/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/0277724 A1 2012/0283645 A1 2012/0283648 A1	10/2012 10/2012 10/2012 11/2012 11/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/027724 A1 2012/0283645 A1 2012/0283648 A1 2012/0283649 A1	10/2012 10/2012 10/2012 11/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/0277724 A1 2012/0283645 A1 2012/0283648 A1	10/2012 10/2012 10/2012 11/2012 11/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/0277724 A1 2012/0283645 A1 2012/0283648 A1 2012/0283649 A1 2012/0283650 A1	10/2012 10/2012 10/2012 11/2012 11/2012 11/2012 11/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. Veasey et al. MacDonald et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/0277724 A1 2012/0283645 A1 2012/0283648 A1 2012/0283649 A1 2012/0283650 A1 2012/0283651 A1	10/2012 10/2012 10/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. Veasey et al. MacDonald et al. Veasey et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/0277724 A1 2012/0283645 A1 2012/0283648 A1 2012/0283649 A1 2012/0283650 A1 2012/0283651 A1 2012/0283652 A1	10/2012 10/2012 10/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. MacDonald et al. MacDonald et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/0277724 A1 2012/0283645 A1 2012/0283649 A1 2012/0283659 A1 2012/0283651 A1 2012/0283652 A1 2012/0283654 A1	10/2012 10/2012 10/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. Veasey et al. MacDonald et al. MacDonald et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/027724 A1 2012/0283645 A1 2012/0283649 A1 2012/0283650 A1 2012/0283651 A1 2012/0283652 A1 2012/0283654 A1 2012/0283654 A1	10/2012 10/2012 10/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. Veasey et al. MacDonald et al. MacDonald et al. Jones et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/027724 A1 2012/0283645 A1 2012/0283648 A1 2012/0283659 A1 2012/0283650 A1 2012/0283652 A1 2012/0283654 A1 2012/0283654 A1 2012/0283660 A1 2012/0283661 A1	10/2012 10/2012 10/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. Veasey et al. MacDonald et al. MacDonald et al. MacDonald et al. Jones et al. Jugl et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/027724 A1 2012/0283645 A1 2012/0283649 A1 2012/0283659 A1 2012/0283651 A1 2012/0283652 A1 2012/0283654 A1 2012/0283654 A1 2012/0283660 A1 2012/0283661 A1 2012/0283661 A1	10/2012 10/2012 10/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. Veasey et al. MacDonald et al. MacDonald et al. MacDonald et al. Jones et al. Jugl et al. Veasey et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/0277724 A1 2012/0283645 A1 2012/0283649 A1 2012/0283659 A1 2012/0283650 A1 2012/0283651 A1 2012/0283654 A1 2012/0283660 A1 2012/0283661 A1 2012/0289007 A1 2012/0289908 A1	10/2012 10/2012 10/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. MacDonald et al. Veasey et al. MacDonald et al. Jones et al. Jugl et al. Veasey et al. Kouyoumjian et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/027724 A1 2012/0283645 A1 2012/0283649 A1 2012/0283659 A1 2012/0283651 A1 2012/0283652 A1 2012/0283654 A1 2012/0283654 A1 2012/0283660 A1 2012/0283661 A1 2012/0283661 A1	10/2012 10/2012 10/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. Veasey et al. MacDonald et al. MacDonald et al. MacDonald et al. Jones et al. Jugl et al. Veasey et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/0277724 A1 2012/0283645 A1 2012/0283649 A1 2012/0283659 A1 2012/0283650 A1 2012/0283651 A1 2012/0283654 A1 2012/0283660 A1 2012/0283661 A1 2012/0289007 A1 2012/0289908 A1	10/2012 10/2012 10/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. MacDonald et al. Veasey et al. MacDonald et al. Jones et al. Jugl et al. Veasey et al. Kouyoumjian et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/027724 A1 2012/0283645 A1 2012/0283649 A1 2012/0283659 A1 2012/0283651 A1 2012/0283654 A1 2012/0283654 A1 2012/0283661 A1 2012/0283661 A1 2012/0283661 A1 2012/0289907 A1 2012/0289908 A1 2012/0289909 A1	10/2012 10/2012 10/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. Veasey et al. MacDonald et al. MacDonald et al. Jugl et al. Veasey et al. MacDonald et al. Jugl et al. Veasey et al. Rouyoumjian et al. Raab et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/027724 A1 2012/0283645 A1 2012/0283645 A1 2012/0283650 A1 2012/0283651 A1 2012/0283651 A1 2012/0283654 A1 2012/0283660 A1 2012/0283661 A1 2012/0283661 A1 2012/0289007 A1 2012/0289908 A1 2012/0289909 A1 2012/0289929 A1 2012/028929 A1	10/2012 10/2012 10/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. Veasey et al. MacDonald et al. MacDonald et al. Jones et al. Jugl et al. Veasey et al. Back et al. Souge et al. Kouyoumjian et al. Raab et al. Nagel et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/027724 A1 2012/0283645 A1 2012/0283645 A1 2012/0283650 A1 2012/0283651 A1 2012/0283651 A1 2012/0283654 A1 2012/0283654 A1 2012/0283661 A1 2012/0283907 A1 2012/0289907 A1 2012/0289909 A1 2012/0289909 A1 2012/0289929 A1 2012/0291778 A1 2012/0291778 A1	10/2012 10/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. MacDonald et al. MacDonald et al. MacDonald et al. Jones et al. Jugl et al. Veasey et al. Kouyoumjian et al. Boyd et al. Nagel et al. Nagel et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/0277724 A1 2012/0283645 A1 2012/0283649 A1 2012/0283649 A1 2012/0283650 A1 2012/0283651 A1 2012/0283654 A1 2012/0283661 A1 2012/0283661 A1 2012/0289907 A1 2012/0289909 A1 2012/0289909 A1 2012/0289909 A1 2012/0289909 A1 2012/0289929 A1 2012/028929 A1 2012/0296276 A1 2012/0296287 A1	10/2012 10/2012 10/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. Veasey et al. MacDonald et al. MacDonald et al. MacDonald et al. Jones et al. Jugl et al. Veasey et al. Kouyoumjian et al. Raab et al. Nagel et al. Nicholls et al. Veasey et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/027724 A1 2012/0283645 A1 2012/0283649 A1 2012/0283659 A1 2012/0283651 A1 2012/0283651 A1 2012/0283654 A1 2012/0283660 A1 2012/0283661 A1 2012/0283661 A1 2012/0289907 A1 2012/0289908 A1 2012/0289908 A1 2012/0289909 A1 2012/0289909 A1 2012/0289929 A1 2012/028929 A1 2012/0291778 A1 2012/029676 A1 2012/0296276 A1 2012/0296278 A1	10/2012 10/2012 10/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. Veasey et al. WacDonald et al. Veasey et al. MacDonald et al. Jones et al. Jugl et al. Veasey et al. Kouyoumjian et al. Raab et al. Boyd et al. Nicholls et al. Veasey et al. Kramer et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/027724 A1 2012/0283645 A1 2012/0283649 A1 2012/0283650 A1 2012/0283651 A1 2012/0283651 A1 2012/0283654 A1 2012/0283654 A1 2012/0283661 A1 2012/0283661 A1 2012/028908 A1 2012/028909 A1 2012/028909 A1 2012/028909 A1 2012/028909 A1 2012/028977 A1 2012/0291778 A1 2012/0296276 A1 2012/029287 A1 2012/0302989 A1 2012/0302989 A1	10/2012 10/2012 10/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. Veasey et al. Veasey et al. MacDonald et al. MacDonald et al. Jones et al. Jugl et al. Veasey et al. Kouyoumjian et al. Raab et al. Boyd et al. Nicholls et al. Veasey et al. Kousey et al. Kousey et al. Kousey et al. Kousey et al. Kousey et al. Kousey et al. Nagel et al. Nicholls et al. Veasey et al. Kramer et al. Brooks et al.
2012/0267761 A1 2012/0271233 A1 2012/0271233 A1 2012/0277124 A1 2012/0283645 A1 2012/0283645 A1 2012/0283650 A1 2012/0283650 A1 2012/0283651 A1 2012/0283654 A1 2012/0283654 A1 2012/0283660 A1 2012/0283661 A1 2012/0283907 A1 2012/0289908 A1 2012/0289909 A1 2012/0289909 A1 2012/0289929 A1 2012/028977 A1 2012/028977 A1 2012/02877 A1 2012/029276 A1 2012/0302989 A1 2012/0302989 A1 2012/0302989 A1 2012/0302989 A1 2012/0302989 A1	10/2012 10/2012 10/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. Veasey et al. Veasey et al. MacDonald et al. MacDonald et al. Jones et al. Jugl et al. Veasey et al. Kouyoumjian et al. Boyd et al. Nagel et al. Nicholls et al. Veasey et al. Boyd et al. Nagel et al. Kramer et al. Brooks et al. Karlsson et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/02771243 A1 2012/0283645 A1 2012/0283645 A1 2012/0283650 A1 2012/0283651 A1 2012/0283651 A1 2012/0283654 A1 2012/0283654 A1 2012/0283660 A1 2012/0283661 A1 2012/0283661 A1 2012/0289097 A1 2012/0289909 A1 2012/0289909 A1 2012/0289909 A1 2012/028929 A1 2012/028929 A1 2012/028929 A1 2012/0302992 A1 2012/0302992 A1 2012/0302992 A1 2012/0302992 A1 2012/0302992 A1 2012/0302992 A1	10/2012 10/2012 10/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. MacDonald et al. Veasey et al. MacDonald et al. MacDonald et al. Jones et al. Jones et al. Jugl et al. Veasey et al. Raab et al. Boyd et al. Nicholls et al. Veasey et al. Nicholls et al. Veasey et al. Kramer et al. Brooks et al. Karlsson et al. Kouyoumjian et al.
2012/0267761 A1 2012/0271233 A1 2012/0271233 A1 2012/0277124 A1 2012/0283645 A1 2012/0283645 A1 2012/0283650 A1 2012/0283650 A1 2012/0283651 A1 2012/0283654 A1 2012/0283654 A1 2012/0283660 A1 2012/0283661 A1 2012/0283907 A1 2012/0289908 A1 2012/0289909 A1 2012/0289909 A1 2012/0289929 A1 2012/028977 A1 2012/028977 A1 2012/02877 A1 2012/029276 A1 2012/0302989 A1 2012/0302989 A1 2012/0302989 A1 2012/0302989 A1 2012/0302989 A1	10/2012 10/2012 10/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. Veasey et al. Veasey et al. MacDonald et al. MacDonald et al. Jones et al. Jugl et al. Veasey et al. Kouyoumjian et al. Boyd et al. Nagel et al. Nicholls et al. Veasey et al. Boyd et al. Nagel et al. Kramer et al. Brooks et al. Karlsson et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/02771243 A1 2012/0283645 A1 2012/0283645 A1 2012/0283650 A1 2012/0283651 A1 2012/0283651 A1 2012/0283654 A1 2012/0283654 A1 2012/0283660 A1 2012/0283661 A1 2012/0283661 A1 2012/0289097 A1 2012/0289909 A1 2012/0289909 A1 2012/0289909 A1 2012/028929 A1 2012/028929 A1 2012/028929 A1 2012/0302992 A1 2012/0302992 A1 2012/0302992 A1 2012/0302992 A1 2012/0302992 A1 2012/0302992 A1	10/2012 10/2012 10/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. MacDonald et al. Veasey et al. MacDonald et al. MacDonald et al. Jones et al. Jones et al. Jugl et al. Veasey et al. Raab et al. Boyd et al. Nicholls et al. Veasey et al. Nicholls et al. Veasey et al. Kramer et al. Brooks et al. Karlsson et al. Kouyoumjian et al.
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/0277724 A1 2012/0283645 A1 2012/0283649 A1 2012/0283649 A1 2012/0283650 A1 2012/0283651 A1 2012/0283651 A1 2012/0283661 A1 2012/0283661 A1 2012/0289007 A1 2012/0289909 A1 2012/0289909 A1 2012/0289909 A1 2012/0289909 A1 2012/0289909 A1 2012/0289909 A1 2012/0289909 A1 2012/0296287 A1 2012/0296287 A1 2012/0302989 A1 2012/0302992 A1 2012/0310156 A1 2012/0310206 A1 2012/0310206 A1	10/2012 10/2012 10/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. MacDonald et al. MacDonald et al. MacDonald et al. Jones et al. Jugl et al. Veasey et al. Kouyoumjian et al. Raab et al. Boyd et al. Nicholls et al. Veasey et al. Kramer et al. Brooks et al. Karlsson et al. Kouyoumjian et al. Karlsson et al. Kouyoumjian et al.
2012/0267761 A1   2012/0271233 A1   2012/0271233 A1   2012/0271243 A1   2012/0271243 A1   2012/027724 A1   2012/0283645 A1   2012/0283645 A1   2012/0283654 A1   2012/0283650 A1   2012/0283651 A1   2012/0283654 A1   2012/0283654 A1   2012/0283654 A1   2012/0283654 A1   2012/0283654 A1   2012/0283654 A1   2012/02836561 A1   2012/0283661 A1   2012/0289097 A1   2012/0289909 A1   2012/0289909 A1   2012/0289909 A1   2012/0296276 A1   2012/0302989 A1   2012/0310206 A1   2012/0310206 A1   2012/0310206 A1   2012/0310206 A1   2012/0310208	10/2012 10/2012 10/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. Veasey et al. Veasey et al. MacDonald et al. Veasey et al. MacDonald et al. Jugl et al. Jugl et al. Veasey et al. Kouyoumjian et al. Raab et al. Boyd et al. Nicholls et al. Veasey et al. Kramer et al. Brooks et al. Kramer et al. Kranson et al. Kouyoumjian et al. Kirchhofer
2012/0267761 A1 2012/0271233 A1 2012/0271243 A1 2012/027724 A1 2012/0283645 A1 2012/0283645 A1 2012/0283649 A1 2012/0283650 A1 2012/0283651 A1 2012/0283654 A1 2012/0283654 A1 2012/0283661 A1 2012/0289907 A1 2012/0289907 A1 2012/0289909 A1 2012/0289909 A1 2012/0289909 A1 2012/0289909 A1 2012/0289909 A1 2012/0289909 A1 2012/0289909 A1 2012/028929 A1 2012/0296287 A1 2012/0296287 A1 2012/0302989 A1 2012/031026 A1 2012/0310206 A1 2012/0310208 A1	10/2012 10/2012 10/2012 11/2012	Kim et al. Bruggemann et al. Plumptre et al. Larsen et al. Veasey et al. Veasey et al. Veasey et al. MacDonald et al. MacDonald et al. MacDonald et al. MacDonald et al. Jugl et al. Veasey et al. Source et al. Jugl et al. Nagel et al. Nicholls et al. Nicholls et al. Kramer et al. Brooks et al. Karlsson et al. Karlsson et al. Kouyoumjian et al. Karlsson et al. Kouyoumjian et al.

2012/0325865 A1	12/2012	Forstreuter et al.
2012/0330228 A1	12/2012	Day et al.
2013/0006191 A1	1/2013	Jugl et al.
2013/0006192 A1	1/2013	Teucher et al.
2013/0006193 A1	1/2013	Veasey et al.
2013/0006310 A1	1/2013	Bottlang et al.
2013/0012871 A1	1/2013	Pommereu
2013/0012884 A1	1/2013	Pommerau et al.
2013/0012885 A1	1/2013	Bode et al.
2013/0018310 A1	1/2013	Boyd et al.
2013/0018313 A1	1/2013	Kramer et al.
2013/0018317 A1	1/2013	Bobroff et al.
2013/0018323 A1	1/2013	Boyd et al.
2013/0018327 A1	1/2013	Dasbach et al.
2013/0018328 A1	1/2013	Jugl et al.
2013/0023830 A1	1/2013	Bode
2013/0030367 A1	1/2013	Wotton et al.
2013/0030378 A1	1/2013	Jugl et al.
2013/0030383 A1	1/2013	Keitel
2013/0030409 A1	1/2013	Macdonald et al.
2013/0035641 A1	2/2013	Moller et al.
2013/0035642 A1	2/2013	Daniel
2013/0035644 A1	2/2013	Giambattista et al.
2013/0035645 A1	2/2013	Bicknell et al.
2013/0035647 A1	2/2013	Veasey et al.
2013/0041321 A1	2/2013	Cross et al.
2013/0041324 A1	2/2013	Daniel
2013/0041325 A1	2/2013	Helmer et al.
2013/0041327 A1	2/2013	Daniel
2013/0041328 A1	2/2013	Daniel
2013/0041347 A1	2/2013	Daniel
2013/0060231 A1	3/2013	Adlon et al.

### FOREIGN PATENT DOCUMENTS

AU	2007253481	11/2007
AU	2007301890	4/2008
AU	2008231897	10/2008
AU	2008309660	4/2009
AU	2008305000	10/2009
AU	2009272992	1/2010
AU	20092929888	4/2010
AU	2009299888	8/2010
	2009326132	8/2011
AU		8/2011
AU	2009326322	
AU	2009326323	8/2011
AU	2009326324	8/2011
AU	2009326325	8/2011
AU	2009341040	9/2011
AU	2010233924	11/2011
AU	2010239762	12/2011
AU	2010242096	12/2011
AU	2010254627	1/2012
AU	2010260568	2/2012
AU	2010260569	2/2012
AU	2010287033	4/2012
AU	2010303987	5/2012
AU	2010332857	7/2012
AU	2010332862	7/2012
AU	2010337136	7/2012
AU	2010338469	7/2012
AU	2010314315	8/2012
AU	2011212490	8/2012
AU	2011212556	8/2012
AU	2011212558	8/2012
AU	2011212561	8/2012
AU	2011212564	8/2012
AU	2011212566	8/2012
AU	2011212567	8/2012
AU	2011214922	8/2012
AU	2011221472	8/2012
AU	2011231688	9/2012
AU	2011231691	9/2012
AU	2011224884	10/2012
AU	2011231570	10/2012
AU	2011231697	10/2012
AU	2011233733	10/2012
AU	2011234479	10/2012
AU	2011238967	11/2012

10/2012 10/2012

10/201210/2012

11/2012

11/2012

11/2012

11/2012 11/2012 11/2012 11/2012 11/2012

12/2012

12/2012

12/2012

12/2012 12/2012 12/2012 1/2013 1/2013

1/2013

1/2013

1/2013

1/2013

1/2013

2/2013 2/2013 2/2013 3/2008 12/2012

12/2009

7/2012

10/2012

10/2012 11/2012

1/2013 1/2013 1/2013 1/2013

2/2013

2/2013

2/2013

9/2012

11/1987

2/1988

4/1990 2/1993 1/2001

5/2003

8/2005

7/2008

4/2010

12/2010 12/2010 12/2010 1/2011

9/2011 12/2011

7/2012

7/2012

8/2012 11/2012

12/2012

12/2012 12/2012 12/2012 1/2013 7/2012

11/2012

12/2012

12/2012

2/2013

3/2010

8/2012

10/2012

5/2008

11/2008

11/2008

2/2009

8/2009

9/2009

11/2009

12/2009 1/2010

3/2010

#### (56) **References** Cited

### FOREIGN PATENT DOCUMENTS

(56)	Refere	nces Cited	CN	102753222
	EQDEICN DAT		CN CN	102753223 102753224
	FOREIGN PAIL	ENT DOCUMENTS	CN	102753224
AU	2011244232	11/2012	CN	102770170
AU	2011244232	11/2012	CN	102770173
AU	2011244237	11/2012	CN	102781499
AU	2011249098	11/2012	CN	102781500
AU	2011262408	12/2012	CN	102802699
AU	2011270934	1/2013	CN CN	102802702 102802703
AU	2011273721	1/2013	CN	102802703
AU AU	2011273722 2011273723	1/2013 1/2013	CN	102821801
AU	2011273723	1/2013	CN	102821802
AU	2011273725	1/2013	CN	102821805
AU	2011273726	1/2013	CN	102834133
AU	2011273727	1/2013	CN CN	102869399 102895718
AU	2011273728	1/2013	CN	102905613
BR BR	0208013 0308262	3/2004 1/2005	CN	102905742
BR	PI712805	10/2012	CN	102905743
BR	PI0713802-4	11/2012	CN	102905744
BR	0214721	12/2012	CN	102905745
CA	2552177	7/1999	CN	102917738
CA	2689022	11/2002	CN DE	102917743 102006041809
CA CA	2473371 2557897	7/2003	DE	202011110155
CA CA	02702412	10/2005 12/2008	DK	1646844
CN	101094700	12/2008	DK	2229201
CN	101128231	2/2008	DK	2023982
CN	101184520	5/2008	DK	2274032
CN	101400394	4/2009	DK DK	02346552 1888148
CN	101405582	4/2009	DK	2288400
CN CN	$101479000 \\ 101511410$	7/2009 8/2009	DK	2373361
CN	101516421	8/2009	DK	1885414
CN	101557849	10/2009	DK	2174682
CN	101563123	10/2009	DK	2310073
CN	101563124	10/2009	EG	25844
CN	101594898	12/2009	EP EP	245895 255044
CN CN	101600468 101605569	12/2009 12/2009	EP	361668
CN	101610804	12/2009	EP	525525
CN	101626796	1/2010	EP	1067823
CN	101678166	3/2010	EP	1307012
CN	101678172	3/2010	EP EP	1140260
CN	101678173	3/2010	EP	1944050 2174682
CN CN	$101687078 \\ 101687079$	3/2010 3/2010	EP	2258424
CN	101687080	3/2010	EP	2258425
CN	101715371	5/2010	EP	02275158
CN	101909673	12/2010	EP	2364742
CN	101912650	12/2010	EP EP	2393062 2471564
CN	101939034	1/2011	EP	02477681
CN CN	101939036 102548599	1/2011 7/2012	EP	02484395
CN	102548601	7/2012	EP	2526987
CN	102548602	7/2012	EP	02529773
CN	102573955	7/2012	EP	02529774
CN	102573958	7/2012	EP EP	02529775 2549789
CN CN	102573960	7/2012	ES	02385630
CN CN	102573963 102630172	7/2012 8/2012	ËŠ	2389866
CN	102630172	8/2012	ES	2392667
CN	102630174	8/2012	ES	02393173
CN	102639170	8/2012	ES	2394556
CN	102639171	8/2012	GB IL	2463034 171247
CN	102648014	8/2012	IL IL	198750
CN CN	102655899 102665800	9/2012 9/2012	JP	5016490
CN	102665802	9/2012	JP	5026411
CN	102686255	9/2012	JP	5033792
CN	102686256	9/2012	JP	5074397
CN	102686258	9/2012	JP	2009-529395
CN	102695531	9/2012	JP	5066177
CN	102695532	9/2012	JP	5039135
CN CN	102711878	10/2012	JP JP	5044625 2010-005414
CN CN	102727965 102740907	10/2012 10/2012	JP JP	2010-005414
0.17	102/10/07	10:2012	51	2010 0 10307

(56)	Refere	nces Cited	KR	20120091153	8/2012
	FOREIGN PATENT DOCUMENTS		KR KR	20120091154 20120095919	8/2012 8/2012
m	1050202	5/2012	KR KR	20120099022 20120099101	9/2012 9/2012
ЛР ЛР	4970282 4970286	7/2012 7/2012	KR	20120099101	9/2012
JP	4972147	7/2012	KR	20120106754	9/2012
JP	4977209	7/2012	KR	20120106756	9/2012
JP	4977252	7/2012	KR MX	20120112503 2012006694	10/2012 7/2012
ЛР ЛР	4979686 4982722	7/2012 7/2012	NO	332622	10/2003
л JP	2012515566	7/2012	NZ	572765	8/2012
$_{\rm JP}$	2012515585	7/2012	NZ	587235	8/2012
JP	2012515587	7/2012	NZ PL	00590352 2023982	10/2012 11/2012
JP JP	2012516168 2012516736	7/2012 7/2012	PT	2023982	10/2012
JP	2012516737	7/2012	PT	2346552	11/2012
JP	4990151	8/2012	RU	2462275	3/2011
JP	4992147	8/2012	RU RU	2459247 2011104496	8/2012 8/2012
JP JP	4994370 5001001	8/2012 8/2012	RU	2460546	9/2012
JP	2012143646	8/2012	RU	2011109925	10/2012
JP	2012148198	8/2012	RU	2011119019	11/2012
ЛР	2012519508	8/2012	SG SG	181710 181790	7/2012 7/2012
JP JP	2012519511 2012519514	8/2012 8/2012	SG	184182	10/2012
JP JP	2012319314 2012176295	9/2012	SG	184328	11/2012
ЛР	2012183322	9/2012	SG	184500	11/2012
JP	2012520128	9/2012	SG SG	184501 184502	11/2012
JP	2012521821	9/2012	SI	2274032	11/2012 12/2012
ЛР ЛР	2012521825 2012521826	9/2012 9/2012	SI	2346552	12/2012
JP	2012521827	9/2012	WO	WO 88/08724	11/1988
JP	2012521828	9/2012	WO	WO 91/13299	9/1991
JP JP	2012521829	9/2012	WO WO	WO 91/13430 WO 94/11041	9/1991 5/1994
JP JP	2012521830 2012521831	9/2012 9/2012	wo	WO 9831369	7/1998
JP	2012521834	9/2012	WO	WO 9832451	7/1998
$_{\rm JP}$	2012522547	9/2012	WO	WO 9922789	5/1999
JP	2012-525172	10/2012	WO WO	WO 9962525 WO 0006228	12/1999 2/2000
JP JP	2012-525180 2012-525185	10/2012 10/2012	wo	WO 02/083216	10/2002
JP	2012523876	10/2012	WO	WO02089805	11/2002
JP	2012525200	10/2012	WO WO	WO03047663 WO03068290	6/2003 8/2003
ЛР ЛР	5084825 2012232151	11/2012 11/2012	WO	WO 03070296	8/2003
JP	2012232131	11/2012	WO	03095003	11/2003
JP	2012528619	11/2012	WO	WO03097133	11/2003
ЛР	2012528620	11/2012	WO WO	WO 2004/041331 WO 2004/047892	5/2004 6/2004
ЛР ЛР	2012528621 2012528622	11/2012 11/2012	WO	WO 2005/005929	1/2005
JP JP	2012528622	11/2012	WO	WO 2005/009515	2/2005
JP	2012528624	11/2012	WO	WO 2005/053778	6/2005
JP	2012528625	11/2012	WO WO	WO 2006/079064 WO 2006/125328	7/2006 11/2006
JP JP	2012528626 2012528627	11/2012 11/2012	WO	WO 2006/120098	12/2006
л ЛР	2012528628	11/2012	WO	WO 2007/063342	6/2007
JP	2012528629	11/2012	WO	WO 2007/100899	9/2007
JP	2012528630	11/2012	WO WO	WO 2007/104636 WO 2007/129106	9/2007 11/2007
JP JP	2012528631 2012528632	11/2012 11/2012	WO	WO 2007/131013	11/2007
JP	2012528632	11/2012	WO	WO 2007/131025	11/2007
JP	2012528634	11/2012	WO	WO 2007/143676	12/2007
JP	2012528635	11/2012	WO WO	WO 2008/005315 WO 2008/009476	1/2008 1/2008
ЛР ЛР	2012528636 2012528637	11/2012 11/2012	WO	WO 2008/058666	5/2008
л ЛР	2012528638	11/2012	WO	WO 2008/071804	6/2008
JP	2012528640	11/2012	WO	WO 2008/100576	8/2008
ЛР	2012530576	12/2012	WO WO	WO 2008/107378 WO 2009049885	9/2008 4/2009
ЛР ЛР	2012532635 2012532636	12/2012 12/2012	WO	WO 2009049885 WO 2009/114542	4/2009 9/2009
JP JP	2012532636	12/2012	wo	WO 2009/114342 WO 2009/132778	11/2009
JP	2012532720	12/2012	WO	WO 2009/141005	11/2009
JP	2012532721	12/2012	WO	WO 2010/003569	1/2010
ЛР	2012532722	12/2012	WO	WO 2010/043533	4/2010
JP JP	5112330 5113847	1/2013 1/2013	WO WO	WO 2010/046394 WO 2010/097116	4/2010 9/2010
JF KR	101160735	7/2012	WO	WO 2010/09/110 WO 2010/108116	9/2010
KR	20120091009	8/2012	WO	WO 2011/023736	3/2011

#### (56) **References** Cited

### FOREIGN PATENT DOCUMENTS

WO	WO 2011/023882	3/2011
WO	WO 2011/035877	3/2011
WO	WO 2011/036133	3/2011
WO	WO 2011/036134	3/2011
WO	WO 2011/039163	4/2011
wõ	WO 2011/039201	4/2011
wo	WO 2011/039201 WO 2011/039202	4/2011
WO	WO 2011/039207	4/2011
WO	WO 2011/039208	4/2011
WO	WO 2011/039209	4/2011
WO	WO 2011/039211	4/2011
WO	WO 2011/039216	4/2011
wõ	WO 2011/039210 WO 2011/039217	4/2011
WO	WO 2011/039218	4/2011
WO	WO 2011/039219	4/2011
WO	WO 2011/039228	4/2011
WO	WO 2011/039231	4/2011
WŎ	WO 2011/039232	4/2011
wo	WO 2011/039232 WO 2011/039233	4/2011
WO	WO 2011/039236	4/2011
WO	WO 2011/040861	4/2011
WO	WO 2011/042537	4/2011
WO	WO 2011/042540	4/2011
WO	WO 2011/043714	4/2011
wõ	WO 2011/045385	4/2011
WO	WO 2011/045385 WO 2011/045386	4/2011
WO	WO 2011/045611	4/2011
WO	WO 2011/046756	4/2011
WO	WO 2011/048223	4/2011
WO	WO 2011/048422	4/2011
WO	WO 2011/050359	4/2011
wo	WO 2011/0503335 WO 2011/053225	5/2011
WO	WO 2011/053225 WO 2011/054648	5/2011
WO	WO 2011/054775	5/2011
WO	WO 2011/056127	5/2011
WO	WO 2011/060087	5/2011
WO	WO 2011/067187	6/2011
WO	WO 2011/067268	6/2011
wõ	WO 2011/067200 WO 2011/067320	6/2011
WO	WO 2011/067615	6/2011
WO	WO 2011/068253	6/2011
WO	WO 2011/069936	6/2011
WO	WO 2011/073302	6/2011
WO	WO 2011/073307	6/2011
WÕ	WO 2011/076280	6/2011
wo	WO 2011/070280 WO 2011/080092	7/2011
WO	WO 2011/081867	7/2011
WO	WO 2011/081885	7/2011
WO	WO 2011/089206	7/2011
wo	WO 2011/089207	7/2011
WO		
	WO 2011/095478	8/2011
WO	WO 2011/095480	8/2011
WO	WO 2011/095483	8/2011

WO	WO 2011/095486	8/2011
WO	WO 2011/095488	8/2011
WO	WO 2011/095489	8/2011
WO	WO 2011/095503	8/2011
WO	WO 2011/099918	8/2011
WO	WO 2011/101349	8/2011
WO	WO 2011/101351	8/2011
WO	WO 2011/101375	8/2011
WO	WO 2011/101376	8/2011
WO	WO 2011/101377	8/2011
WO	WO 2011/101378	8/2011
WO	WO 2011/101379	8/2011
WO	WO 2011/101380	8/2011
WO	WO 2011/101381	8/2011
WO	WO 2011/101382	8/2011
WO	WO 2011/101383	8/2011
WO	WO 2011/107805	9/2011
WO	WO 2011/109205	9/2011
WO	WO 2011/110464	9/2011
WO	WO 2011/110465	9/2011
WO	WO 2011/110466	9/2011
WO	WO 2011/111006	9/2011
WO	WO 2011/112136	9/2011
WO	WO 2011/113806	9/2011
WO	WO 2011/117212	9/2011
WO	WO 2011/117284	9/2011
WO	WO 2011/117404	9/2011
WO	WO 2011/121003	10/2011
WO	WO 2011/121061	10/2011
WO	WO 2011/123024	10/2011
WO	WO 2011/124634	10/2011
WO	WO 2011/126439	10/2011
WO	WO 2012020084	2/2012
WO	WO 2012022771	2/2012
WO	WO 2012/090186	7/2012
WO	WO 2011/051366	9/2012
WO	WO 2012/122643	9/2012

### OTHER PUBLICATIONS


Written Opinion for International Patent Application No. PCT/ US2013/029085, dated May 13, 2013, 5 pages.


US2013/029085, dated May 13, 2013, 5 pages. International Patent Application No. PCT/US14/23883, Interna-tional Search Report, dated Jul. 10, 2014, 3 pages. International Patent Application No. PCT/US14/23485, Interna-tional Search Report, dated Jul. 7, 2014, 2 pages. International Patent Application No. PCT/US14/24530, Interna-tional Search Report, dated Jul. 15, 2014, 2 pages. International Patent Application No. PCT/US14/24543, Interna-tional Search Report dated Jul. 28, 2014, 2 pages.


tional Search Report, dated Jul. 28, 2014, 2 pages. Japanese Office Action dated Jul. 7, 2016 for Japanese patent application No. 2014-561030.

European Office Action dated Jun. 21, 2016 for EP patent applica-tion No. 13757994.2.

\* cited by examiner















FIG.4















FIG.10A



# FIG. 10B




FIG. 11

10

### PREFILLED SYRINGE WITH BREAKAWAY FORCE FEATURE

### CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority of U.S. Provisional Patent Application No. 61/607,339 filed Mar. 6, 2012, which is incorporated by reference herein for all purposes.

#### BACKGROUND OF THE INVENTION

The present invention relates to a jet injector and in some embodiments a needle-assisted jet injector that uses a low jet injection pressure and has a lock ring that provides breakaway force resistance.

Certain jet injection devices have needle guards that must be retracted prior to insertion of the needle and triggering of the jet injection. A certain amount of force is normally 20 required to trigger the jet injection. To assure sufficient needle guard travel for needle insertion and triggering, it is at times desirable to require a breakaway force prior to significant needle guard retraction to assure that insertion of the needle and triggering of triggering force is overcome. 25 The present invention addresses this problem.

### SUMMARY OF THE INVENTION

In certain embodiments, the invention relates to a jet 30 injector. In one embodiment, the jet injector includes a prefilled syringe having a container portion defining a fluid chamber containing a medicament; an injection-assisting needle disposed at the distal end of the chamber, having an 35 injecting tip configured for piercing an insertion location, and defining a fluid pathway in fluid communication with the chamber for injecting the fluid from the chamber into an injection site; a plunger movable within the fluid chamber; a housing that houses the prefilled syringe and is configured for allowing insertion of the needle at the injection location to an insertion point that is at a penetration depth below the surface, the housing including: a retractable guard that is movable between a protecting position in which the needle is disposed within the guard and an injecting position in 45 which the tip of the needle is exposed for insertion to the insertion point, and an interference component adjacent to the retractable guard that interferes with the movement of the retractable guard when the retractable component is moved at least partially from the protecting position toward 50 the injecting position; a syringe support supportively mounting the prefilled syringe in the housing; an energy source configured for biasing the plunger with a force selected to produce an injecting pressure on the medicament in the fluid chamber to jet inject the medicament from the fluid chamber 55 through the needle to the injection site.

In certain embodiments, the energy source and prefilled syringe are configured such that the injecting pressure remains between about 80 p.s.i. and about 1000 p.s.i. during injection of the medicament. In one embodiment, the energy 60 source and prefilled syringe are configured such that the injecting pressure remains below about 500 p.s.i. and above about 90 p.s.i. during the injection of the medicament. In another embodiment, the energy source and prefilled syringe are configured to produce the injecting pressure that remains 65 at least at about 100 p.s.i. during the injection of the medicament. In one embodiment, the energy source and

prefilled syringe are configured such that the injecting pressure remains up to about 350 p.s.i. during the injection of the medicament.

In certain embodiments, the prefilled syringe has a distal portion in which the injection-assisting needle is located, and a proximal portion opposite the distal portion; and the syringe support axially supports the proximal portion of the pre-filled syringe during the jet injection of the medicament, such that the distal portion of the prefilled syringe is substantially unsupported in an axial direction. In one embodiment, the container portion of the pre-filled syringe is made of blown glass. In another embodiment, the injection-assisting needle is adhered to the glass.

In certain embodiment, the interference component is a ring having at least one abutment arm extending distally from a proximal end dimensioned to fit within the housing, the abutment arm having at least one tapered portion. In one embodiment, the at least one abutment arm has an engagement portion axially adjacent to the at least one tapered portion that is configured to cause resistance to the movement of the retractable guard when the retractable guard is moved at least partially from the protecting position toward the injecting position.

In one embodiment, the energy source comprises a spring. In one embodiment, the jet injector further includes a ram that is biased by the spring against the plunger to produce the injecting pressure, wherein the ram comprises a bell portion on which the spring is seated, and the bell portion defines a hollow interior configured for receiving the prefilled syringe when the device is fired, such that the spring surrounds the prefilled syringe.

In some embodiments, the jet injector further includes a trigger mechanism operably associated with the energy source for activating the energy source to jet inject the medicament, wherein the trigger mechanism is configured for activating the energy source after the retractable guard is retracted from the protecting position. In one embodiment, the retractable guard is operably associated with the trigger mechanism to cause the trigger mechanism to activate the energy source when the guard is retracted to the injecting position.

In some embodiments, the interference component is a sleeve having an engagement portion extending outwardly from an outer surface of the sleeve that is configured to cause resistance to the movement of the retractable guard when the retractable guard is moved at least partially from the protecting position toward the injecting position. In other embodiments, the interference component is a latch coupled to the housing that is configured to cause resistance to the movement of the retractable guard when the retractable guard is moved at least partially from the protecting position toward the injecting position.

In certain embodiments, the housing is configured for allowing insertion of the needle to the penetration depth, which is between about 0.5 mm and about 5 mm below the surface at the insertion location.

In certain embodiments, the housing is configured for allowing insertion of the needle to the penetration depth, which is between about 11 mm and about 13 mm below the surface at the insertion location.

In certain embodiments, the chamber contains about between 0.02 mL and about 4 mL of the medicament.

In certain embodiments, the penetration depth and injecting pressure are sufficient to substantially prevent backflow of the injected medicament. 20

In other embodiments, the jet injector further includes a syringe cushion associated with the syringe support and prefilled syringe to compensate for shape irregularities of the pre-filled syringe.

In certain embodiments, the invention relates to a lock <sup>5</sup> ring for a jet injector. In other embodiments, the lock ring includes at least one abutment arm extending distally from a proximal end of a body dimensioned to fit within in a housing of the jet injector, the abutment arm having at least one tapered portion and at least one engagement portion <sup>10</sup> axially adjacent to the at least one tapered portion, the engagement portion being configured to cause resistance to the movement of a retractable guard of the jet injector; and at least one flap radially adjacent to the at least one abutment <sup>15</sup> arm extending distally from the proximal end of the body.

# BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

The foregoing summary, as well as the following detailed description of embodiments of the present invention, will be better understood when read in conjunction with the appended drawings of exemplary embodiments. It should be understood, however, that the invention is not limited to the 25 precise arrangements and instrumentalities shown.

In the drawings:

FIG. **1** is a side view of an embodiment of a jet injector constructed according to the present invention, showing the injector prior to injection;

FIG. **2** is a cross-sectional view of the jet injector of FIG. **1** thereof taken along plane II-II;

FIG. **3** is a perspective view of a prefilled syringe for use in the jet injector of FIG. **1**;

FIG. **4** is a perspective view of a syringe cushion of the <sup>35</sup> jet injector of FIG. **1**;

FIG. **5** is a cross-sectional view of the jet injector of FIG. **1**, showing the injector at the start of the jet injection;

FIG. **6** is a graph showing the pressure present in the polluted chamber over time that contains medicament in an <sup>40</sup> embodiment during jet injection;

FIG. **7** is a side view of another embodiment of an injector that is configured for using a narrow diameter prefilled syringe;

FIG. **8** is a cross-sectional view of the jet injector of FIG. 45 **1**; taken along plane VIII-VIII;

FIG. 9 is a cross-sectional view of another embodiment of an injector using a needle for intramuscular jet-injection;

FIG. **10**A is a side view of an interference component of a jet injector in accordance with an exemplary embodiment; <sup>50</sup>

FIG. **10B** is a perspective view of an interference component of a jet injector in accordance with an exemplary embodiment: and

FIG. **11** is a graph showing the breakaway force over time of how of an jet injector in accordance with an exemplary embodi- 55 syringe. A syr

#### DETAILED DESCRIPTION OF THE INVENTION

With reference to the accompanying drawings, various embodiments of the present invention are described more fully below. Some but not all embodiments of the present invention are shown. Indeed, various embodiments of the invention may be embodied in many different forms and 65 should not be construed as limited to the embodiments expressly described. Like numbers refer to like elements

throughout. The singular forms "a," "an," and "the" include the singular and plural unless the context clearly dictates otherwise.

Referring to FIGS. 1 and 2, an embodiment of an injector 10 has a housing 12 configured for allowing a user to handle the injector 10. The housing 12 includes an outer housing member 14 that substantially houses most of the components shown in FIG. 2. A syringe support member 16 is housed within and mounted with the housing 12. The syringe support member 16 is configured to hold and position a prefilled syringe 18, which is shown in FIG. 3. In one embodiment, the syringe support member 16 is substantially fixed to the housing 12, such as by snaps, an adhesive, a weld, or another known attachment. The prefilled syringe 18 has a container portion 20 that defines in its interior a fluid chamber 22, which is prefilled with medicament to be injected. At the distal end of the prefilled syringe 18 is an injection-assisting needle 24. Needle 24 has an injecting tip 26 configured as known in the art to penetrate the tissue of a patient, in certain embodiments, the skin of the patient. A needle bore extends through the needle 24, as known in the art. The bore is in fluid communication with the medicament in the fluid chamber 22 and is open at the needle tip 26 to inject the medicament.

At a proximal side of the fluid chamber 22, opposite from the needle 24, is a plunger 28 that seals the medicament in the fluid chamber 22. In certain embodiments, a syringe wall 30 comprises a tubular portion, in some embodiments closed at a distal end and open at a proximal end, to define the fluid chamber 22. Plunger 28 is slideably received in the tubular portion. The prefilled syringe 20 is configured such that when the plunger 28 is displaced in a distal direction, the volume of the fluid chamber 22 is decreased, forcing the medicament out therefrom and through the bore of the needle 24.

At the distal end of the fluid chamber 22 is a needle hub portion 32 to which the needle is mounted. In one embodiment, a syringe flange 34 extends radially from the proximal end of the syringe wall 30.

In one embodiment, the syringe 18 has a syringe body 36 that includes the flange 34, wall 30 and hub portion 32. In one embodiment, syringe body 36 that includes flange 34, wall 30, and hub portion 32 is of unitary construction. A preferred material for the syringe body 36 is glass, but other materials can be used in other embodiments. A suitable prefilled syringe is the BD Hypak<sup>TM</sup>, which is available in various sizes and volumes and is sold prefilled with medicament. The glass of the syringe body 36 is adhered to the needle 24. Typical medicaments and medicament categories include epinephrine, atropine, sumatriptan, antibiotics, antidepressants, and anticoagulants. Using a prefilled syringe 18 facilitates handling of the medicament when the injector 10 is assembled, and there is an extensive body of knowledge of how the medicaments keep and behave in a prefilled syringe.

A syringe cushion **38**, which is shown in detail in FIG. **4**, is in certain embodiments made of an elastomeric material or other resilient material. A flange **40** of the syringe cushion **38** extends radially and is disposed and serves as an interface between the distal side of the syringe support member **16** and the syringe flange **34**. Elevated portions, such as nubs **42** extend proximately from the cushion flange **40** and are configured and dimensioned to abut the syringe flange **34**.

Prefilled syringes that are manufactured by a blown glass process can have significant dimensional tolerances and unevenness, particularly in the glass body **36**. The cushion **38** can serve to accommodate the shape irregularities and to properly position and locate the prefilled syringe 18 within the syringe support 16. Typically, the axial thickness of glass blown syringe flanges on a 1 mL prefilled syringe is within about ±0.5 mm. For a BD Hypak<sup>™</sup> 1 mL standard prefilled syringe, the thickness of the syringe flange 34 is 2 mm+0.5 5 mm or -0.4 mm, and in a 1 mL long configuration BD Hypak<sup>™</sup> syringe, the flange axial thickness is about 1.65 mm±0.25 mm. Other dimensional variations that occur in typical glass prefilled syringes are in the internal and external diameters of the tubular wall 30. These variations can be 10 accommodated by the resilient sleeve portion 44 of the syringe cushion 38, which extends axially around the interior of the syringe support 16. In one embodiment, the syringe cushion 38 is received in the interior of the syringe support member 16 and receives the syringe body 36, in 15 certain embodiments fitting snugly therein.

In one embodiment, the sleeve portion 44 has radially inwardly extending protrusions 46 with a surface area and configuration selected to allow the insertion of the prefilled syringe 18 therein during assembly, but providing sufficient 20 friction to maintain the syringe 18 in place and to provide cushioning and shock absorption during the firing of the injector 10. Outward protrusions 48 are also provided on the sleeve portion 44, which can be received in corresponding recesses of the syringe support 16 to prevent axial rotation 25 component 134, e.g., a lock ring, adjacent to the needle therebetween. Recessed areas 50 can be provided on the interior and exterior of the syringe cushion 38 opposite corresponding protrusions 48 on the opposite radial side of the sleeve portion 44 if an increased wall thickness of the sleeve portion 44 is not desired. In an alternative embodi- 30 ment one or both of the flange 40 and sleeve 44 of the syringe cushion 38 are substantially smooth, substantially without any protrusions. In one embodiment, the material and configuration of the syringe cushion 38 is also sufficient to entirely support the prefilled syringe 20 to withstand a 35 firing force applied axially in a distal direction on the plunger 28. Thus, the entire support for the prefilled 20 can be provided on the syringe flange 34, while the distal end of the syringe 18 may itself be substantially unsupported in an axial direction. This can help withstand the shock on the 40 glass body 36 of the prefilled syringe 20 produced by the elevated pressures within the fluid chamber 22.

To radially position the distal end of the prefilled syringe 18, the syringe support 16 in certain embodiments has a narrowed bore portion 51 that is in certain embodiments 45 configured to abut the outside of the syringe wall 30. This is especially beneficial when the needle 24 is inserted into the patient's skin. The narrowed bore portion 51 can be made of a resilient material, such as an elastomer, or it can be made unitarily with the rest of the syringe support 16, in certain 50 embodiments of a plastic material.

Referring to FIG. 2, in one embodiment, a trigger mechanism 52 is also housed within housing 12. The trigger mechanism 52 includes an inner housing 54 that can be attached to the outer housing 14, such as by snaps, an 55 adhesive, a weld, or other known attachment. Trigger protrusions 56 extend inwardly from the proximal end of the inner housing 54 and are resiliently biased outwardly. Trigger protrusions 56 are received in a recess 58 of ram 60 in blocking association therewith to prevent distal movement 60 of the ram 60 prior to the firing of the device. The ram 60 is urged towards the distal end of the injector 10 by an energy source, which in certain embodiments is a compression spring 52, although other suitable energy sources can alternative be used such as elastomer or compressed-gas 65 springs. In one embodiment, the compression spring is a coil spring.

6

A trigger member of the trigger mechanism 52, such as a latch housing 64, is provided exterior to the inner housing to retain the trigger protrusions 56 in the blocking association in the recess 58 to prevent premature firing of the injector 10. The latch housing 64 is slideable inside the outer housing 14 with respect to the inner housing 54, in certain embodiments in an axial direction, and the latch housing 64 in certain embodiments surrounds the inner housing 54.

The housing 12 has a needle guard 66 that is moveable with respect to the outer housing 14. The needle guard 66 is shown in FIGS. 1 and 2 in a protecting position, in which the needle 24 is disposed within the guard 66. The needle guard 66 is retractable, in one embodiment into the outer housing 14, in a proximal direction to an injecting position, in which the needle tip 26 and an end portion of the needle 24 is exposed as shown in FIG. 5 for insertion into a patient. In one embodiment, the proximal movement of the guard is prevented substantially at the injecting position.

In one embodiment, an interference component 134 interferes with the movement of the needle guard when the needle guard is moved at least partially from the protecting position toward the injecting position.

In one embodiment, the housing 12 has an interference guard 66, the interference component 134 interferes with the movement of the needle guard when the needle guard is moved at least partially from the protecting position toward the injecting position. Interference component prevents movement of the needle guard until the breakaway force 146 is exceeded. The interference component 134 is shown in FIGS. 10A and 10B. In one embodiment, the interference component 134 is included as part of a ring having at least one abutment arm 136 extending distally from a proximal end 138 dimensioned to fit within the housing 14, the abutment arm 136 having at least one tapered portion 140. The abutment arm 136 may also have an engagement portion 142 axially adjacent to the at least one tapered portion 140 that is configured to cause resistance to the movement of the needle guard 66 when the needle guard 66 is moved at least partially from the protecting position toward the injecting position. While interference component 134 may have more than one abutment arm 136 and correspondingly more than one engagement portion 142, certain embodiments include only one abutment arm 136 having an engagement portion 142. The interference component may also include at least one flap 144 radially adjacent to the at least one abutment arm 136 extending distally from the proximal end 138 of the interference component 134.

The interference component 134 may also be coupled to the housing 12, incorporated in a sleeve separate from the housing 12, or include a latch.

Referring to FIG. 11, breakaway force 146 is needed to overcome the resistance on the needle guard 66 caused by the engagement portion 142 when the needle guard 66 is moved at least partially from the protecting position toward the injecting position. Referring to FIG. 11, breakaway force 146 is the resistance to retraction that is exerted on the needle guard 66 when an initial attempt to retract the needle guard 66 occurs. Breakaway force 146 is a distinct force from the triggering force 148 that is needed to cause jet injection of the medicament and is a greater force than that provided by the spring 62 that biases the needle guard 66 in the extended position. Breakaway force 146 is sometimes also a greater force than what occurs due to the friction of the needle guard 66 retracting motion sliding on other

mating components in the device. In one embodiment the breakaway force **146** is controlled and only occurs as a single event.

Referring to FIG. 2, the needle guard 66 is associated with the latch housing 64 such that when the guard 66 is displaced 5 distally it slides the latch housing 64 also in a distal direction to release the trigger protrusions 56 from the recess 58. In one embodiment, the latch housing 64 has a latching portion 68 that abuts the inner housing 54 in an association to bias and maintain the trigger protrusions 58 positioned in the 10 blocking association with the ram 60 prior to the firing of the device 10. When the latch is slid proximately by the retracting of the guard 66 to the injecting position, the latching portion 68 slides beyond the portion of inner housing 54 that is contacts to flex the trigger protrusions 56 into the recess 15 58 of the ram 60, allowing the trigger protrusions 56 to move radially outwardly from the recess 58 and therefore from the blocking association. When this happens, spring 62 biases the ram 60 against plunger 28 to fire the jet injector 10. In certain embodiments, latch housing 64 defines trigger open- 20 ings 70 adjacent to latching portions 68, which is configured to receive a portion of the inner housing 54, such as the surface disposed radially outwardly from the trigger protrusions 56.

In certain embodiments, the guard **66** is resiliently biased 25 distally towards the protecting position by compression coil spring **72**. Also, the needle guard **66** has an axial opening **74** to allow the needle **24** pass there through, and which may be sized according to the type of injector desired. The construction of the present embodiment allows a user to push 30 the distal end of the injector **10** against the patient's skin, pushing the needle **24** into the skin at an insertion location, substantially at the same speed as the injector is pushed. Once the needle **24** is fully inserted to an insertion point at a penetration depth, the trigger mechanism **56** fires the jet 35 injection to an injection site.

Referring to FIG. 5, in one embodiment, the prefilled syringe 18 and its needle 24 are not shuttled forward automatically into the patient's skin, such as by the firing energy source during the injection firing. The user preferably 40 gently pushes the entire device forward to insert the needle 24, in certain embodiments retracting a guard against the skin in the process. In one embodiment, the prefilled syringe 18 is substantially stationary within the housing 12, and, in one embodiment, is substantially fixed thereto. In this man- 45 ner, the present invention provides for a gentler treatment of the syringe during injection that enables the use of a sufficiently powerful spring 62 or other energy source to produce a jet injection without the risk of damaging the relatively fragile and complex shapes of the prefilled syringe, also 50 allowing, for example, the injection of high viscosity solutions, where the risk of breaking a syringe, such as at the flange, is elevated in prior art injectors that shuttle the syringe forward in the housing and into the patient. Residual stresses are also often present in the glass bodies of prefilled 55 syringes, and this configuration reduces the additional stresses imposed thereon during use, further protecting the syringe. Also, misalignments in the prefilled syringe are also rendered operationally less significant due to the gentle insertion of the needle that is possible with this configura- 60 tion

In one embodiment, the injecting position of the guard **66** is such that a predetermined length of the end of needle **24** is exposed from the guard **66**. In some embodiments, such as where the opening **74** is of a sufficiently large diameter, 65 the skin of the patient maybe allowed to extend into the opening **74** when the device **10** is pressed there against, and

a needle that does not protrude beyond the distal end of the guard 66 can be used while still penetrating the skin to a certain depth. In most embodiments, the distance 76 by which the needle tip 26 extends past the distal end of the guard 66 will be fairly close to the depth of the insertion of the needle.

In one embodiment, such as for subcutaneous injection, the guard 66 is configured to allow insertion of the needle 24 to a penetration depth in the skin that is up to about 5 mm below the skin surface. In another embodiment, the penetration depth is less than about 4 mm, and in one embodiment is less than about 3 mm. In one embodiment, the insertion depth is at least about 0.5 mm and, in other embodiments, at least about 1 mm. In another embodiment, the distance 76 by which the needle extends past the guard 66 or the distal surface of the guard 66 that contacts the skin is up to about 5 mm, in one embodiment, up to about 4 mm, and in another embodiment up to about 3 mm. In certain embodiments, extension distance 76 is at least about 0.5 mm, in one embodiment at least about 1 mm, and in another embodiment at least about 2 mm. In one embodiment, tip 26 extends by a distance 76 of around 2.5 mm beyond the portion of the guard 66 that contacts the skin in the injecting position.

In another embodiment, such as for intramuscular injection, the injector is configured to allow the needle 24 to be inserted into the patient to a penetration depth in the skin, or alternatively beyond the distal surface of the guard, by a distance of up to about 15 mm. In one embodiment, this distance is about between 10 mm and 14 mm. In an embodiment for jet injection of epinephrine for instance, a penetration depth or distance beyond the guard is between about 11 mm and about 17.0 mm, and, in other embodiments, between about 13 to about 15 mm. Jet injection with this length needle improves the distribution of the medicament in the patient tissue compared to non jet injection. Other exposed needle lengths can be selected for jet injection to different depths below the skin, with, in certain embodiments, an overall penetration length of between about 0.5 mm and about 20 mm. In certain embodiments, the needle guard is configured for retracting from a protecting position, in one embodiment covering the entire needle 24 (See FIG. 2), to an injecting position, in which the desired length of the end of the needle 24 is exposed (See FIG. 5).

In some embodiments, the spring 62 and the prefilled syringe 18 are configured to jet inject the medicament. Thus, the spring 62 applies a force on the plunger 28 that is sufficient to elevate the pressure within the fluid chamber 22 to a level high enough to eject the medicament from the needle 24 as a jet. Jet injection is to be understood as an injection with sufficient velocity and force to drive the medicament to locations remote from the needle tip 26. In manual and autoinjector-type injections, in which the injection pressures are very low, the medicament exits the needle tip inside the patient and is typically deposited locally around the needle in a bolus. On the other hand, with the present jet injection device 10, the medicament is jet injected distally or in other directions, such as generally radially by the elevated pressure jet, which beneficially improves the distribution of the medicament after the injection and keeps a large bolus from forming that can detrimentally force the medicament to leak back out of the patient around the needle or through the hole left behind by the needle after it is removed.

Referring to the graph shown in FIG. 6, numeral **78** represents the point in time when device **10** is fired, and numeral **80** represents the point in time of completion of the medicament injection, in certain embodiments when the

plunger 28 hits the forward wall of the container portion 20. Numeral 82 represents the initial and peak pressure during the injection, and numeral 84 represents the final and low pressure during the injection. Since the spring 62 of one embodiment has a linear spring constant and an injection-<sup>5</sup> assisting needle is used to puncture the skin before commencing the injection, the pressure drops substantially linearly from the start of the injection 78 until the injection is completed. The final pressure 84 at the end 80 of the injection is sufficiently elevated so that even at the end of the firing stroke of ram 60, the medicament is still jet injected, and a very small amount or none of the medicament is deposited in a bolus around the needle tip 26.

In one embodiment, the peak pressure during the injection 15 is less than about 1,000 p.s.i., in one embodiment less than about 500 p.s.i., and in another embodiment less than about 350 p.s.i. At the end 80 of the injection, the pressure 84 applied to the medicament in the fluid chamber 22 is in one embodiment at least about 80 p.s.i., in one embodiment at 20 least about 90 p.s.i., and in another embodiment at least about 100 p.s.i. In one embodiment of the invention, the initial pressure 82 is around 330 p.s.i., and the final pressure is about 180 p.s.i., while in another embodiment the initial pressure 82 is about 300 p.s.i., dropping to around 110 p.s.i. <sup>25</sup> at the end 80 of the injection. The needles used in these embodiments are between 26 and 28 gauge, and are in certain embodiments around 27 gauge, but alternatively other needle gages can be used where the other components are cooperatively configured to produce the desired injection. In an embodiment for jet injection of epinephrine for instance, certain embodiments of the needles are between 20 and 25 gauge, and in other embodiments, 22 gauge. In one embodiment, the components of the injector 10 are config-35 ured to jet inject the medicament to a subterraneous injection site

The amount of medicament contained and injected from fluid chamber 22 is in one embodiment between about 0.02 mL and about 4 mL, in certain embodiments less than about  $_{40}$ 3 mL, and in other embodiments is around 1 mL. Larger volumes may also be selected depending on the particular medicament and dosage required. In one embodiment, the prefilled syringe is assembled into the remaining parts of the jet injector 10 already containing the desired amount of  $^{45}$ medicament. In one embodiment, the prefilled syringe contains about 1 mL of medicament.

In one embodiment, injection rates are below about 0.75 mL/sec., in one embodiment preferably below about 0.6 mL/sec., in one embodiment at least about 0.2 mL/sec., in <sup>50</sup> one embodiment at least about 0.3 mL/sec, and in other embodiments at least about 0.4 mL/sec. In one embodiment, the injection of the entire amount of medicament is completed in less than about 4 seconds, in one embodiment in less than about 3 seconds, and in other embodiments in less than about 2.5 seconds. In one embodiment, the medicament injection takes at least about 1 second, in one embodiment at least 1.5 seconds, and in other embodiments at least about 1.75 seconds. In one embodiment, the injector **10** injects the medicament at about 0.5 mL/sec., completing the injection of 1 mL in about 2 seconds.

U.S. Pat. No. 6,391,003 discloses several experimental results of pressures that can be applied to medicament in a glass cartridge, using 26 and 27 gauge needles. The follow- 65 ing table illustrates injections with different peak pressures that can be used with glass prefilled syringes:

1	Ω	
	U.	

Pressure and Time (sec.) to Inject 1 cc		
Pressure	26 Gauge needle	27 Gauge needle
150 p.s.i.	2.1	4.2
200 p.s.i.	1.9	3.9
240 p.s.i.	1.7	3.3
375 p.s.i.	1.4	3.1

It is foreseen that higher pressures and flow rates will be used with shorter needle penetration into the patient skin to achieve jet injections to a particular desired depth substantially without medicament leakback.

It has been found that using the jet injection of the present device, short needles can be used to inject medicament to different parts of the skin, in certain embodiments subcutaneously, substantially without any leakback. Using a needle **24** that extends by about 2.5 mm from the needle guard **66**, a 27 gauge needle **24**, and a pressure in the fluid chamber **22** peaking at around 300 p.s.i. and ending at around 100 p.s.i., resulting in a flow rate of about 0.5 mL/sec., 1 mL of medicament has been found to successfully be injected without leakback in close to 100% of the tested injections. Thus, the needle-assisted jet injector **10** of the present invention permits jet injection of the medicament using a very short needle reliably regardless of the thickness of the patient's skin or the patient's age, weight or other typical factors that complicate non-jet injecting with short needles.

FIGS. 7 and 8 show another embodiment of the present invention that uses a prefilled syringe that has a long, but smaller-diameter configuration than the embodiment of FIG. 2. While in the embodiment of FIG. 2, the firing spring 62 extends into the bore of the prefilled syringe 18 during the firing stroke, the narrower prefilled syringe 88 of injector 86 does not provide as much space to accommodate a spring. Consequently, the ram 90 of injector 86 includes a bell portion 92 defining a hollow interior 94 that is configured to receive the proximal end of the prefilled syringe 88 and the syringe support 96 when the injector 86 is fired. Similarly, a bell-receiving space 98 is defined around the exterior of the prefilled syringe 88 and syringe support 96 to receive the bell portion 92 during the firing. The bell portion 92 includes a spring seat 100 extending radially outwardly and configured and disposed to seat a compression spring 102. When the trigger mechanism 56 is activated and the device 86 is fired, spring 102 acts against seat 100 to drive the ram 90 against plunger 104 to jet inject the medicament from the fluid chamber 106. As a result, after firing, the spring 102 radially surrounds the prefilled syringe 88. The outer housing portion 108 is wider than outer housing portion 14 of injector 10 to accommodate the bell portion 92 and larger diameter spring 102.

One available long configuration syringe with a 1 mL capacity has a cylindrical syringe body portion with a diameter of 8.15 mm, which would in certain embodiments be used in the injector of FIGS. 7 and 8, while one available shorter configuration syringe of the same capacity has a cylindrical syringe body portion with a diameter of 10.85 mm, which would in certain embodiments be used in the injector of FIGS. 1 and 2. While the embodiment with a bell portion 92 can be used with wider/shorter syringes, in certain embodiments, the prefilled syringes have an outer diameter cylindrical wall of less than about 10 mm, and in other embodiments less than about 9 mm.

Injector **86** also includes a cap **110** fitted around the needle guard **66**, and associated with the outer housing **108** to prevent retraction of the needle guard **66** and the triggering

of the device **86**. Additionally, the cap **110** seals off the needle tip **26** and can be removed prior to using the device **86**. In one embodiment, the cap **110** is configured to fit over the needle guard **66** in a snap-fit association therewith, such as by including a narrower diameter portion **112** associated **5** with an enlarged diameter portion **114** of the needle guard **66**.

Additionally, injector **86** employs a syringe cushion cap **116** that extends around the outside of the syringe flange **34** from the syringe cushion **118** to help trap and retain the 10 prefilled syringe **88**. In one embodiment, a cushion cap **122** is connected to the cushion **118** and is, in certain embodiments, of unitary construction therewith. The cushion cap **122** abuts the distal end of the syringe body **120** to radially position and hold the proximal end of the body **120** while the 15 needle **24** is being inserted into the patient. Similarly to the embodiment of FIG. **2**, the syringe holder **96** is associated with the housing in a substantially fixed position, such as by mounting portion **124**, which traps protrusions **126** of the syringe holder. 20

Referring to FIG. 9, injector 128 has a needle guard 130 configured to retract further into the injector housing than the injector of FIGS. 1 and 2 or FIG. 5 before the trigger mechanism 52 fires the jet injection. The injector in this figure is shown in a position in which the trigger mechanism 25 52 is being released and about to fire the injection. The distance 76 by which the needle extends past the guard 130 or the distal surface of the guard 130 that contacts the skin in certain embodiments between about 12.5 and 13 mm. In one embodiment, the guard is preferably configured to 30 reextend to a protecting position after the device is fired and removed from the patient, such as under the bias of spring 72, and is locked in that position by locking members 132, as known in the art to prevent reuse on the injector.

In other embodiments, the guard length, the location of 35 the guard injecting position with respect to the needle tip (including the guard throw between the protecting and injecting positions), and the length of the needle from the syringe body can be selected to allow for shallower or deeper needle insertions before the device is fired, providing 40 lesser or greater distances **76**, respectively. In one embodiment, the guard is kept from sliding further back than substantially at the firing position, to better control in insertion depth into the patient.

Each and every reference herein is incorporated by ref- 45 erence in its entirety. The entire disclosure of U.S. Patent Application 2011/0144594, U.S. Pat. Nos. 8,021,335 and 6,391,003 are hereby incorporated herein by reference thereto as if fully set forth herein.

While illustrative embodiments of the invention are disclosed herein, it will be appreciated that numerous modifications and other embodiments may be devised by those skilled in the art. For example, the features for the various embodiments can be used in other embodiments, such as the needle and guard cap of FIGS. **7** and **8**, which can be applied 55 to the embodiment of FIG. **1**. Therefore, it will be understood that the appended claims are intended to cover all such modifications and embodiments that come within the spirit and scope of the present invention.

What is claimed is:

1. A jet injector, comprising:

a prefilled syringe comprising:

a container portion defining a fluid chamber containing a medicament and defining a longitudinal axis therethrough;

60

65

an injection-assisting needle disposed at the distal end of the chamber, having an injecting tip configured for piercing an insertion location, and defining a fluid pathway in fluid communication with the chamber for injecting the fluid from the chamber into an injection site;

a plunger movable within the fluid chamber;

- a housing that houses the prefilled syringe and is configured for allowing insertion of the needle at the injection location to an insertion point that is at a penetration depth below the surface, the housing comprising:
  - a retractable guard that is movable between a protecting position in which the needle is disposed within the guard and an injecting position in which the tip of the needle is exposed for insertion to the insertion point, and
- an interference component adjacent to the retractable guard, the interference component being a ring having at least one abutment arm, the abutment arm having at least one tapered portion and an engagement portion axially adjacent to the at least one tapered portion, the engagement portion comprising a surface angled relative to an incline of the tapered portion, the angled surface of the engagement portion extending radially outward relative to the longitudinal axis and from a proximal end of the tapered portion and is configured to block and cause resistance to the movement of the retractable guard when the retractable guard is moved at least partially from the protecting position toward the injecting position;
- a syringe support supportively mounting the prefilled syringe in the housing;
- an energy source configured for biasing the plunger with a force selected to produce an injecting pressure on the medicament in the fluid chamber to jet inject the medicament from the fluid chamber through the needle to the injection site.

**2**. The jet injector of claim **1**, wherein the energy source and prefilled syringe are configured such that the injecting pressure remains between about 80 p.s.i. and about 1000 p.s.i. during injection of the medicament.

**3**. The jet injector of claim **2**, wherein the energy source and prefilled syringe are configured such that the injecting pressure remains below about 500 p.s.i. and above about 90 p.s.i. during the injection of the medicament.

**4**. The jet injector of claim **2**, wherein the energy source and prefilled syringe are configured to produce the injecting pressure that remains at least at about 100 p.s.i. during the injection of the medicament.

**5**. The jet injector of claim **4**, wherein the energy source and prefilled syringe are configured such that the injecting pressure remains up to about 350 p.s.i. during the injection of the medicament.

**6**. The jet injector of claim **1**, wherein the prefilled syringe has a distal portion in which the injection-assisting needle is located, and a proximal portion opposite the distal portion;

and the syringe support axially supports the proximal portion of the pre-filled syringe during the jet injection of the medicament, such that the distal portion of the prefilled syringe is substantially unsupported in an axial direction.

7. The jet injector of claim 6, wherein the container portion of the pre-filled syringe is made of blown glass.

**8**. The jet injector of claim **7**, wherein the injection-assisting needle is adhered to the glass.

**9**. The jet injector of claim **1**, wherein the ring is dimensioned to fit within the housing.

**10**. The jet injector of claim **1**, wherein the energy source comprises a spring.

11. The jet injector of claim 10, further comprising a ram that is biased by the spring against the plunger to produce the injecting pressure, wherein the ram comprises a bell portion on which the spring is seated, and the bell portion defines a hollow interior configured for receiving the prefilled syringe <sup>5</sup> when the device is fired, such that the spring surrounds the prefilled syringe.

**12**. The jet injector of claim **1**, further comprising a trigger mechanism operably associated with the energy source for activating the energy source to jet inject the medicament, <sup>10</sup> wherein the trigger mechanism is configured for activating the energy source after the retractable guard is retracted from the protecting position.

**13**. The jet injector of claim **12**, wherein the retractable used is operably associated with the trigger mechanism to cause the trigger mechanism to activate the energy source when the guard is retracted to the injecting position.

14. The jet injector of claim 1, wherein the interference component is a sleeve having an engagement portion <sup>20</sup> extending outwardly from an outer surface of the sleeve that is configured to cause resistance to the movement of the retractable guard when the retractable guard is moved at least partially from the protecting position toward the injecting position.

**15.** The jet injector of claim **1**, wherein the interference component is a latch coupled to the housing that is configured to cause resistance to the movement of the retractable guard when the retractable guard is moved at least partially from the protecting position toward the injecting position.  $_{30}$ 

**16**. The jet injector of claim **1**, wherein the housing is configured for allowing insertion of the needle to the penetration depth, which is between about 0.5 mm and about 5 mm below the surface at the insertion location.

17. The jet injector of claim 1, wherein the housing is  $_{35}$  configured for allowing insertion of the needle to the penetration depth, which is between about 11 mm and about 13 mm below the surface at the insertion location.

18. The jet injector of claim 1, wherein the chamber contains about between 0.02 mL and about 4 mL of the  $_{40}$  medicament.

**19**. The jet injector of claim **1**, wherein the penetration depth and injecting pressure are sufficient to substantially prevent backflow of the injected medicament.

**20**. The jet injector of claim **1**, further comprising a 45 syringe cushion associated with the syringe support and prefilled syringe to compensate for shape irregularities of the pre-filled syringe.

21. A jet injector, comprising:

a prefilled syringe comprising:

a container portion defining a fluid chamber containing a medicament and defining a longitudinal axis therethrough;

an injection-assisting needle disposed at the distal end of the chamber, having an injecting tip configured for piercing an insertion location, and defining a fluid pathway in fluid communication with the chamber for injecting the fluid from the chamber into an injection site;

a plunger movable within the fluid chamber;

- a housing that houses the prefilled syringe and is configured for allowing insertion of the needle at the injection location to an insertion point that is at a penetration depth below the surface, the housing comprising:
  - a retractable guard that is movable between a protecting position in which the needle is disposed within the guard and an injecting position in which the tip of the needle is exposed for insertion to the insertion point, and
  - an interference component adjacent to the retractable guard, the interference component having at least one abutment arm, the abutment arm having at least one tapered portion and an engagement portion axially adjacent to the at least one tapered portion, the engagement portion comprising a surface angled relative to an incline of the tapered portion, the angled surface of the engagement portion extending radially outward relative to the longitudinal axis and from a proximal end of the tapered portion and is configured to block and cause resistance to the movement of the retractable guard when the retractable guard is moved at least partially from the protecting position toward the injecting position;
- a syringe support supportively mounting the prefilled syringe in the housing;
- an energy source configured for biasing the plunger with a force selected to produce an injecting pressure on the medicament in the fluid chamber to jet inject the medicament from the fluid chamber through the needle to the injection site.

22. The jet injector of claim 21, wherein the interference component is a ring having a proximal end and a distal end, the at least one abutment arm extending distally from the proximal end of the ring, the ring being dimensioned to fit within the housing.

\* \* \* \* \*